| Title | T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. |
| Publication Type | Journal Article |
| Year of Publication | 2022 |
| Authors | Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim S-B, Tajika M, Lockhart ACraig, Arkenau H-T, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, Cao ZAlexander, Lunceford J, Suryawanshi S, Ayers M, Marton MJ, Kato K |
| Journal | Future Oncol |
| Date Published | 2022 Jul 19 |
| ISSN | 1744-8301 |
| Abstract | Aim: Investigate the relationship between response to pembrolizumab and expression of the 18-gene T cell-inflamed gene expression profile (TcellinfGEP) or PD-L1 combined positive score (CPS) in esophageal cancer. Materials & methods: This analysis included heavily pretreated patients with advanced/metastatic esophageal/gastroesophageal junction adenocarcinoma or squamous cell carcinoma who received pembrolizumab in the single-arm, phase II study KEYNOTE-180. PD-L1 CPS was evaluated with PD-L1 IHC 22C3 pharmDx. Results: In patients with squamous cell carcinoma, trends toward enrichment for responders were observed for patients with PD-L1 CPS ≥10 tumors. In patients with adenocarcinoma, a trend was observed for TcellinfGEP but not for PD-L1. Conclusion: TcellinfGEP and PD-L1 CPS may enrich for responders to pembrolizumab in patients with esophageal cancer. Clinical trial registration: NCT02559687 (ClinicalTrials.gov). |
| DOI | 10.2217/fon-2021-1134 |
| Alternate Journal | Future Oncol |
| PubMed ID | 35852104 |
| Grant List | / / by Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA / |